Health Catalyst, Inc.(HCAT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,447 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
HCAT Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Health Catalyst, Inc. (HCAT), a Technology sector company. 13F Pro's AI-powered ranking engine scores HCAT at 28.1/100 on a 32-signal composite quality model, placing it at rank #2,447 of 2,879 stocks — the bottom half of the AI-ranked universe. HCAT scores in the top quartile across institutional flow (86.0). Areas of concern include balance sheet strength (5.0) and profitability (8.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 18.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Health Catalyst, Inc. reports quarterly revenue of $70.8M, net income of $-111.0M, free cash flow of $18.2M. Top institutional holders of HCAT by reported 13-F value include First Light Asset Management,, CDC Financial,, BlackRock,, based on the most recent SEC filings. HCAT trades on the Nasdaq exchange and files with the SEC under CIK 1636422. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HCAT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Health Catalyst, Inc. directly from SEC EDGAR. Health Catalyst, Inc.'s 13F Pro composite quality score has ranged between 8 and 51 since 2021, currently 28.1 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.
Revenue
Q1 2026
$70.8M
Net Income
Q1 2026
$-111.0M
Free Cash Flow
Q1 2026
$18.2M
D/E Ratio
Q1 2026
1.12
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+11.0% YoYNet Income
+49.4% YoYOperating Income
+50.1% YoYEPS (Diluted)
+56.3% YoYTotal Assets
+14.2% YoYTotal Debt
+170.9% YoYOp. Cash Flow
+141.3% YoY| Metric | FY 2024 | FY 2022 | FY 2021 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Revenue | $306.6M +11.0% | $276.2M +14.2% | $241.9M +114.9% | $112.6M +54.0% | $73.1M | — |
| Net Income | $-69.5M +49.4% | $-137.4M +10.3% | $-153.2M -147.2% | $-62.0M -31.8% | $-47.0M | — |
| Operating Income | $-69.8M +50.1% | $-140.0M +2.5% | $-143.7M -139.0% | $-60.1M -32.0% | $-45.5M | — |
| EPS (Diluted) | $-1.15 +56.3% | $-2.63 +18.6% | $-3.23 | — | — | — |
| Total Assets | $858.9M +14.2% | $752.3M -9.6% | $832.1M +649.8% | $111.0M | — | — |
| Total Debt | $613.5M +170.9% | $226.5M +25.2% | $180.9M +800.2% | $20.1M | — | — |
| Operating Cash Flow | $14.6M +141.3% | $-35.3M -52.5% | $-23.1M +42.6% | $-40.3M -9.4% | $-36.8M | — |
Get alerted when HCAT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Health Catalyst, Inc. including:
Top Institutional Holders of HCAT
First Light Asset Management, LLC
$16.4M12,878,700 shCDC Financial, Inc.
$8.0M6,307,054 shBlackRock, Inc.
$6.5M5,138,022 shWhetstone Capital Advisors, LLC
$5.4M4,268,141 shPalogic Value Management, L.P.
$3.7M2,896,600 shVANGUARD CAPITAL MANAGEMENT LLC
$3.7M2,885,653 shImpax Asset Management Group plc
$3.5M2,750,000 shNepsis Inc.
$2.4M1,876,289 shWhetstone Capital Advisors, LLC
$1.9M1,515,000 shGEODE CAPITAL MANAGEMENT, LLC
$1.9M1,501,433 sh
| Fund | Value | Shares |
|---|---|---|
| First Light Asset Management, LLC | $16.4M | 12,878,700 |
| CDC Financial, Inc. | $8.0M | 6,307,054 |
| BlackRock, Inc. | $6.5M | 5,138,022 |
| Whetstone Capital Advisors, LLC | $5.4M | 4,268,141 |
| Palogic Value Management, L.P. | $3.7M | 2,896,600 |
| VANGUARD CAPITAL MANAGEMENT LLC | $3.7M | 2,885,653 |
| Impax Asset Management Group plc | $3.5M | 2,750,000 |
| Nepsis Inc. | $2.4M | 1,876,289 |
| Whetstone Capital Advisors, LLC | $1.9M | 1,515,000 |
| GEODE CAPITAL MANAGEMENT, LLC | $1.9M | 1,501,433 |
More Technology Companies
View all Technology →Put HCAT on your watchlist
Track score changes the day Health Catalyst, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is HCAT a good stock to buy?
13F Pro's AI-powered analysis of Health Catalyst, Inc. (HCAT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HCAT are available on the HCAT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own HCAT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HCAT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Health Catalyst, Inc.'s investment landscape.